ORTHOCELL LIMITED (OCC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

OCC - ORTHOCELL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.06
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.61

01 Nov
2024

-0.010

OPEN

$0.63

-1.61%

HIGH

$0.63

1,913,148

LOW

$0.61

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-3.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx5.3 M
Book Value Per Share xxxxxxxxxxxxxxx2.2
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.5 M
Net Profit Margin xxxxxxxxxxxxxxx-135.10 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-134.46 %
Return on Invested Capital xxxxxxxxxxxxxxx-123.77 %
Return on Assets xxxxxxxxxxxxxxx-25.55 %
Return on Equity xxxxxxxxxxxxxxx-134.46 %
Return on Total Capital xxxxxxxxxxxxxxx-195.77 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx21 M
Price To Book Value xxxxxxxxxxxxxxx16.40

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.9 M
Capex % of Sales xxxxxxxxxxxxxxx17.72 %
Cost of Goods Sold xxxxxxxxxxxxxxx2 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx15 M
Research & Development xxxxxxxxxxxxxxx9 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

25/10/2024

1

Buy

$1.32

116.39%

Petra Capital notes Orthocell reported record revenue of $2.03m for 1QFY25, up 15% year-on-year and 8% quarter-on-quarter.

The broker highlights growing traction for both Striate-plus and Remplir products, with over 150 surgeons across A&NZ now using Remplir.

The recent approval of Remplir in Singapore marks its first regulatory success outside A&NZ, with a launch expected in 1Q2025.

The broker has lifted its price target to $1.32 from $1.28, maintaining a Buy rating. Financial forecasts for FY25 and FY26 remain largely unchanged, while the FY27 net profit forecast is reduced by -19%.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.10 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.80 cents.
Access Extra Coverage Research History >

OCC STOCK CHART

FNArena News on OCC

1
Australian Broker Call *Extra* Edition – Oct 25, 2024

Oct 25 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Jun 19, 2024

Jun 19 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – May 08, 2024

May 08 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Feb 16, 2024

Feb 16 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Nov 15, 2023

Nov 15 2023 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps